Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Fred Hutch researchers launch free online tool to assess CRC risk

Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.

January 09, 2026

Vol.52 No.1

Drugs & Targets

China NMPA approves Pimicotinib as systemic treatment in tenosynovial giant cell tumor

The China National Medical Products Administration approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

January 09, 2026

Vol.52 No.1

Clinical Roundup

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.

December 19, 2025

Vol.51 No.46

Clinical Roundup

USC researchers develop new CAR T with more controlled immune response in mice

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those that typically escape detection, with fewer toxic side effects.

December 12, 2025

Vol.51 No.45

Guest Editorial

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

December 05, 2025

Vol.51 No.44

By Paul J. Limburg

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

China NMPA approves Pimicotinib as systemic treatment in tenosynovial giant cell tumor

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

USC researchers develop new CAR T with more controlled immune response in mice

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Renew today!

Subscriber content

Never miss an issue!

Login